{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is DermTech, Inc. overvalued or undervalued?
As of March 10, 2020, DermTech, Inc. is classified as "risky" and overvalued, with key financial ratios indicating significant distress compared to peers like Cardiff Oncology and Lucid Diagnostics, while Pro-Dex stands out as very attractive.
Is DermTech, Inc. technically bullish or bearish?
As of September 3, 2024, DermTech, Inc. is in a mildly bearish trend, influenced by daily moving averages, while weekly indicators show mixed signals, leading to a cautious outlook.
Who are in the management team of DermTech, Inc.?
As of March 2022, DermTech, Inc.'s management team includes Independent Chairman Ms. Cynthia Collins, CEO Dr. John Dobak, and several independent directors: Mr. Gary Jacobs, Mr. Scott Pancoast, Mr. Enrico Picozza, Mr. Matthew Posard, and Mr. Herman Rosenman. This team provides governance and strategic direction for the company.
How big is DermTech, Inc.?
As of December 2023, DermTech, Inc. has an unavailable market capitalization. As of March 2024, net sales for the latest four quarters total 15.67 million, with a consolidated net profit of -89.62 million, and shareholder's funds are 57.17 million against total assets of 121.93 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
